Compreendendo a Ocorrência e as Características dos Subtipos Moleculares do Câncer de Mama no Centro-Oeste Paulista, São Paulo

Leandro Verolezi Nunes; Kaue Mendonça Adão; Gabriela Mazete Braz Paião; Luciana Pereira Silva; Gabriel Vitor da Silva Pinto

doi:10.32635/2176-9745.RBC.2026v72n2.5545

Authors

Leandro Verolezi Nunes Fundação Educacional "Miguel Mofarrej" (FEMM), Centro Universitário das Faculdades Integradas de Ourinhos (Unifio). Ourinhos (SP), Brasil. https://orcid.org/0009-0005-9353-2843
Kaue Mendonça Adão Universidade Estadual Paulista (Unesp), Faculdade de Ciências, Humanidades e Letras, Departamento de Biotecnologia, Laboratório de Fitoterápicos e Produtos Naturais. Assis (SP), Brasil. https://orcid.org/0009-0001-6717-1643
Gabriela Mazete Braz Paião Fundação Educacional do Município de Assis (Fema), Faculdade de Ciências da Saúde, Departamento de Enfermagem, Laboratório de Enfermagem. Assis (SP), Brasil. https://orcid.org/0009-0009-8278-768X
Luciana Pereira Silva Universidade Estadual Paulista (Unesp), Instituto de Química. Araraquara (SP), Brasil. Fema. Assis (SP), Brasil. https://orcid.org/0000-0002-0914-2094
Gabriel Vitor da Silva Pinto Centro Universitário das Faculdades Integradas de Ourinhos (Unifio), Núcleo Docente Estruturante (NDE), Coordenação do Estágio de Análises Clínicas do Curso de Biomedicina. Ourinhos (SP), Brasil. Faculdade de Medicina de Marília (Famema). Marília (SP), Brasil. https://orcid.org/0000-0003-4630-9057

DOI:

https://doi.org/10.32635/2176-9745.RBC.2026v72n2.5545

Keywords:

Breast Neoplasms/immunology, Receptors, Cell Surface, Immunohistochemistry, Epidemiology, Oncology

Abstract

Introduction: Breast cancer is one of the main public health challenges, highly incident with significant impact on female morbimortality. Its molecular heterogeneity reflects different clinical behaviors and prognoses, reinforcing the importance of immunophenotypic characterization for therapeutic guidance and diagnostic improvement. Objective: Analyze the distribution of molecular subtypes of breast cancer in patients treated at the oncology service in Ourinhos, São Paulo, between 2017 and 2023. Method: Retrospective, descriptive, and observational study based on the review of medical records and the identification of cellular markers for the classification of luminal A-like, luminal B-like, luminal B/HER2, HER2-positive, and triple-negative subtypes. Statistical analysis was performed using the chi-square test of independence, with a significance level of 0.05. A total of 505 cases were analyzed, with the luminal B subtype being the most prevalent (51.1%), followed by luminal A (21.4%). Results: A statistically significant association was observed between age groups and molecular subtypes (p=0.0235), with a higher frequency of aggressive tumors, as HER2-positive and triple-negative in younger women. Conclusion: The results demonstrate that different age groups in the region present predominant characteristics according to age, highlighting the importance of understanding the local epidemiological profiles of breast cancer.

Downloads

Download data is not yet available.

References

Instituto Nacional de Câncer. Data and numbers on breast cancer: annual report 2022 [Internet]. Rio de Janeiro: INCA; 2022 [acesso 2024 ago 1]. Disponível em: https://www.inca.gov.br/publicacoes/relatorios/dados-e-numeros-sobre-cancer-de-mama-relatorio-anual-2023

Carvalho FFB, Pinto TJP, Knuth AG. Physical activity and cancer prevention: evidence, reflections, and notes for the Unified Health System. Braz J Cancerol. 2020;66(2):e12886. doi: https://doi.org/10.32635/2176-9745.RBC.2020v66n2.886 DOI: https://doi.org/10.32635/2176-9745.RBC.2020v66n2.886

Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. Nat Rev Dis Primers. 2019;5(66):1-31. doi: https://doi.org/10.1038/s41572-019-0111-2 DOI: https://doi.org/10.1038/s41572-019-0111-2

Coelho AS, Santos MAS, Caetano RI, et al. Hereditary predisposition to breast cancer and its relationship with the BRCA1 and BRCA2 genes: literature review. RBAC. 2018;50(1):17-21. doi: https://doi.org/10.21877/2448-3877.201800615 DOI: https://doi.org/10.21877/2448-3877.201800615

Forbes C, Fayter D, Kock S, et al. Systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer. Cancer Manag Res. 2019;11:2321-37. doi: https://doi.org/10.2147/cmar.s189627 DOI: https://doi.org/10.2147/CMAR.S189627

Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature. 2000;406:747-52. doi: https://doi.org/10.1038/35021093 DOI: https://doi.org/10.1038/35021093

Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869-74. doi: https://doi.org/10.1073/pnas.191367098 DOI: https://doi.org/10.1073/pnas.191367098

Cirqueira MB, Moreira MAR, Soares LR, et al. Molecular subtypes of breast cancer. Femina. 2011;39(10):499-503.

Goldhirsch A, Wood WC, Caates AS, et al. Strategies for subtypes dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 2011;22(8):1736-47. doi: https://doi.org/10.1093/annonc/mdr304 DOI: https://doi.org/10.1093/annonc/mdr304

Zanetti JS, Oliveira LR, Silva AR. Breast cancer: from molecular profiles to stem cells. J Univ Vale Rio Verde [Internet]. 2011[acesso 2025 nov 9];9(1):277-92. Disponível em: https://dialnet.unirioja.es/servlet/articulo?codigo=4002371 DOI: https://doi.org/10.5892/RUVRV.91.277292

Peppercorn J, Perou CM, Carey LA. Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest. 2009;26(1):1-10. doi: https://doi.org/10.1080/07357900701784238 DOI: https://doi.org/10.1080/07357900701784238

Schmid P, Cortes J, Aktan G, et al. VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC. Ann Oncol. 2021;32(9):1198-200. doi: https://doi.org/10.1016/j.annonc.2021.06.014 DOI: https://doi.org/10.1016/j.annonc.2021.06.014

BioEstat® [Internet]. Versão 5.3. Belém, PA: Instituto de Desenvolvimento Sustentável Mamirauá; 2007. [Acesso 2024 ago 15]. Disponível em: http://www.mamiraua.org.br/pt-br/downloads/programas/

World Health Organization. Health in all policies: Helsinki statement – framework for country action [Internet]. Geneva: World Health Organization, 2014. [acesso 2025 jan 15]. Disponível em: https://www.who.int/publications/i/item/9789241506908

Conselho Nacional de Saúde (BR). Resolução nº 466 de 12 de dezembro de 2012. Aprova diretrizes e normas regulamentadoras de pesquisas envolvendo seres humanos. Diário Oficial da União, Brasília, DF. 2013 jun 13; Edição 112; Seção 1:59.

Conselho Nacional de Saúde (BR). Resolução n° 510, de 7 de abril de 2016. Dispõe sobre as normas aplicáveis a pesquisas em Ciências Humanas e Sociais cujos procedimentos metodológicos envolvam a utilização de dados diretamente obtidos com os participantes ou de informações identificáveis ou que possam acarretar riscos maiores do que os existentes na vida cotidiana, na forma definida nesta Resolução [Internet]. Diário Oficial da União, Brasília, DF. 2016 maio 24 [acesso 2025 abr 7]; Seção 1:44. Disponível em: http://bvsms.saude.gov.br/bvs/saudelegis/cns/2016/res0510_07_04_2016.html

Pereira HJ, Prestes ALO, Mansani F, et al. Câncer de mama em mulheres jovens: uma análise do estadiamento clínico inicial e dos subtipos moleculares dos tumores. Rev Bras Mastologia. 2019;29(2):83-91. doi: https://doi.org/10.5327/Z201400010004RBM DOI: https://doi.org/10.5327/Z201400010004RBM

Simon SD, Bines J, Werutsky G, et al. Characteristics and prognosis of stage I–III breast cancer subtypes in Brazil: the AMAZONA retrospective cohort study. Breast. 2019;44:113-9. doi: https://doi.org/10.1016/j.breast.2019.01.008 DOI: https://doi.org/10.1016/j.breast.2019.01.008